Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
September 07, 2022 07:00 ET
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
August 11, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
October 19, 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors
September 09, 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
June 08, 2020 08:15 ET
|
Cognition Therapeutics, Inc.
New York, June 08, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting
October 15, 2019 08:03 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
November 27, 2018 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
October 02, 2018 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other ...
Nobilis Therapeutics Receives a Notice of Allowance for a Patent Covering Treatment of Psychiatric Disorders With Noble Gases
June 12, 2017 18:57 ET
|
Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of...